Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure ...

New research shows how gender-affirming hormones influence Cardiac Troponin I levels after one year of treatment. Read more.

Patients with dilated cardiomyopathy have an increased risk of papillary muscle scarring (papSCAR), which was found to be independently associated with cardiac death, heart failure events, and ...

In a phase 2b trial, danicamtiv, a novel cardiac myosin activator, was well tolerated and associated with improved heart ...

Some cells, such as immune cells, are highly mobile—they constantly remodel their shape, migrate toward a wound that needs to ...

Get to know the functions of your heart, blood vessels, and blood itself and how they work together to maintain your health.

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA ...

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trial HOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmission Company preparing to resubmit CRL response ...

Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy has come up short at the FDA, with the regulator rejecting the biotech’s application seeking regulatory approval for what the ...

Cardiac rehabilitation (CR) has evolved from foundations as a postmyocardial infarction mobilization strategy for patients who were typically unstable, into a comprehensive, multidisciplinary program ...

1 Department of Kinesiology, University of Maryland School of Public Health, College Park, Maryland, MD, United States 2 Baltimore Veterans Affairs Geriatric Research, Education and Clinical Center, ...